Recently in the news there was an important report regarding the cholesterol-lowering drug ezetimibe – being marketed as Zetia.
A trial comparing the drug to niacin was halted mid-stream.
Why? Most likely because the result was not what they expected. It doesn’t improve HDL. It also increases the thickness of artery walls.